Kala Pharmaceuticals Announces $22.5 Million Series B Financing

por Ysios Capital

Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform technology, today announced it has comp...

Leer más
Subscribirse al Directorio
Escribir un Artículo

Destacadas

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology

El regreso del mercado de OPVs: un paso ...

by Qualitas Funds

Es importante destacar que la relevancia de los mercados de OPVs va mÃ...

Diapositiva de Fotos